Psychedelic Science Accelerator
An organization connecting psychedelic research projects with impact investors and philanthropists, accelerating the transition from academic science to clinical infrastructure.
Type: research
Location: San Francisco, California
Membership: Research and investor community
Venues: Primarily online; Bay Area hub
Activities: Research grants, investor-researcher connections, policy analysis, clinical network development
About
The Psychedelic Science Accelerator (PSA) operates at the intersection of research, philanthropy, and impact investment in the psychedelic medicine space. It works to reduce funding bottlenecks between academic researchers with promising projects and investors or philanthropists with capital to deploy.
The PSA maintains relationships with clinical trial investigators, academic institutions, and the investment community. It conducts due diligence on research projects, provides policy analysis to inform funding decisions, and facilitates connections that would not easily happen through other channels.
As psychedelic medicine moves toward FDA approval and the formation of a commercial therapy sector, organizations like PSA play a critical role in ensuring that clinical infrastructure (trained therapists, licensed facilities, insurance pathways) develops alongside the regulatory work.
Why It Matters
The transition from research to clinical infrastructure requires capital that neither academic grants nor pharmaceutical development alone can provide. PSA-type organizations bridge this gap and help ensure the field has the infrastructure to serve patients when treatments are approved.
State Legal Context
See current psilocybin laws in California.